Last reviewed · How we verify
NCT07237750: iWAIST-RCT
iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss
NA trial testing Endoscopic Radial Compression Gastroplasty in Overweight and/or Obesity in 216 participants. Currently enrolling.
30 December 2026
Quick facts
| Lead sponsor | Liu Yan |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 216 |
| Start date | 1 March 2026 |
| Primary completion | 30 December 2026 |
| Estimated completion | 31 May 2027 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Endoscopic Radial Compression Gastroplasty
- Optimized Lifestyle Intervention (OLI)
Conditions studied
- Overweight and/or Obesity — all drugs for Overweight and/or Obesity →
- Metabolic Syndrome — all drugs for Metabolic Syndrome →
- Nonalcoholic Fatty Liver Disease — all drugs for Nonalcoholic Fatty Liver Disease →
- Chinese — all drugs for Chinese →
Sponsor
Liu Yan
Who can join
Adults 18 to 65, any sex, with Overweight and/or Obesity or Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Obesity and overweight are rising in Chinese populations, where metabolic risks begin at lower BMI thresholds than in Western cohorts. Many individuals with overweight or mild-to-moderate obesity are ineligible or unwilling to undergo bariatric surgery due to invasiveness and risk. Endoscopic bariatric and metabolic therapies offer minimally invasive alternatives but vary in complexity, cost, and safety profiles. Investigators developed a sutureless endoscopic procedure, Endoscopic Radial Compression Gastroplasty (ERCG), which reduces gastric volume by apposing gastric walls using a clip-and-loop system. This randomized controlled trial evaluates the efficacy and safety of ERCG versus an optimized lifestyle intervention in Asian adults with BMI 24.0-37.4 kg/m² who have not succeeded with conservative measures. Preliminary studies suggest ERCG can achieve approximately 12% total body weight loss (TBWL) at 3 months. The primary endpoint is percent TBWL at 3 months; secondary outcomes include changes in BMI, metabolic parameters, quality of life, and adverse events. Results are expected to inform the role of ERCG as a safe, effective, and scalable option between conservative care and bariatric surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07237750
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Overweight and/or Obesity
Currently open trials in the same condition.
- NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting
- NCT07501377 — Effects of a 6-months Fiber- and Polyphenol-rich Diet on Brain Inflammatory Processes in Perimenopausal Women Living Wit · NA · recruiting
- NCT07400653 — A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) · Phase 3 · recruiting
- NCT07243171 — A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tab · Phase 1, PHASE2 · recruiting
- NCT07085923 — Norwegian Mental Illness Heart Health Study · NA · recruiting
Other Liu Yan trials
Trials by the same sponsor.
- NCT07186959 — EGPSS for Weight Management in an in Vivo Human Model · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07237750 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liu Yan
- Last refreshed: 13 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07237750.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing